No Data
No Data
Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.
Express News | Marker Therapeutics Inc - MT-601 Well Tolerated With No Icans Observed
Marker Therapeutics Announces $16.1 Million Private Placement
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients With Lymphoma
Marker Therapeutics Shares Are Trading Higher After the Company Announced It Won a $9.5 Million Grant to Study Pancreatic Cancer Therapy.
Express News | Marker Therapeutics Inc: Anticipates Clinical Program Initiation in 2025